Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30355542 | 0.90 | PGR (0.35) | LRRK2IRAK4USP2MAPK1HDAC1 | |
| SCHEMBL23523921 | 0.90 | PGR (0.35) | LRRK2IRAK4USP2MAPK1HDAC1 | |
| SCHEMBL25857250 | 0.87 | LRRK2 (0.39) | LRRK2IRAK4SYK | |
| SCHEMBL23524014 | 0.78 | HDAC1 (0.32) | USP2MAPK1HDAC1 | |
| SCHEMBL23524413 | 0.77 | LRRK2 (0.37) | LRRK2SYKHDAC1 | |
| SCHEMBL30355730 | 0.77 | LRRK2 (0.37) | LRRK2SYKHDAC1 | |
| SCHEMBL25857251 | 0.76 | GSK3B (0.35) | — | |
| SCHEMBL23524286 | 0.72 | BRD4 (0.39) | LRRK2IRAK4 | |
| SCHEMBL30355625 | 0.72 | BRD4 (0.39) | LRRK2IRAK4 | |
| SCHEMBL30355580 | 0.71 | DYRK1A (0.42) | LRRK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | LRRK2 2882/4885IRAK4 1340/4885ATR 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.